Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effects of statin therapy on mortality and the risk of subsequent cardiovascular outcomes in kidney transplant recipients
To evaluate the effects of statin therapy on graft function, including the incidence of acute rejection and chronic allograft nephropathy.
To evaluate the effects of statin therapy on the risk of acute transplant rejection.
To evaluate the risk of drug or dosage related adverse events when statin therapy is used in kidney transplant recipients.
To evaluate the effects of statin therapy on mortality and the risk of subsequent cardiovascular outcomes in kidney transplant recipients
To evaluate the effects of statin therapy on graft function, including the incidence of acute rejection and chronic allograft nephropathy.
To evaluate the effects of statin therapy on the risk of acute transplant rejection.
To evaluate the risk of drug or dosage related adverse events when statin therapy is used in kidney transplant recipients.
| Original language | English |
|---|---|
| Article number | CD005019 |
| Journal | Cochrane Database of Systematic Reviews |
| Issue number | 2 |
| Publication status | Published - 21 Jan 2009 |
Keywords
- kidney transplantation
- cardiovascular disease
- Lipoprotein profile
Fingerprint Dive into the research topics of 'HMG CoA reductase inhibitors (statins) for kidney transplant recipients'. Together they form a unique fingerprint.
Cite this
Navaneethan, S. D., Perkovic, V., Nigwekar, S. U., Johnson, D. W., Craig, J. C., & Strippoli, G. F. M. (2009). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews, (2), [CD005019].